IDEAYA Biosciences Partners with Hengrui Pharma to Develop SHR-4849 for Treating SCLC and NET Solid Tumors
Shots:
- IDEAYA has signed an exclusive license agreement with Hengrui Pharma to develop & commercialize SHR-4849 (DLL3-targeting Topo-I-payload ADC) globally (excl. Greater China)
- As per the terms, Hengrui is entitled for $75M upfront, up to $200M development & regulatory milestones, plus commercial success-based milestones, making it a total of $1.045B as well as mid-single to low-double digit net-sales based royalties
- SHR-4849 is currently under P-I evaluation for advanced solid tumors in China. Study (as of Dec 10, 2024) showed ORR of ~73% (8 PRs) in 11 evaluable SCLC patients, with MTD not reached; TRAEs were mostly Grade 1/2 without drug-related discontinuations. IDEAYA plans to file a US IND in H1’25
Ref: IDEAYA Biosciences | Image: IDEAYA Biosciences & Hengrui Pharma
Related News:- IDEAYA Biosciences Collaborates with Biocytogen to Develop Bispecific ADC Program for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
